{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:08Z","timestamp":1758937208222,"version":"3.44.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["CAMN107AKR11T"],"award-info":[{"award-number":["CAMN107AKR11T"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.leukres.2022.106791","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T11:16:03Z","timestamp":1642418163000},"page":"106791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"114","author":[{"given":"Hyunkyung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungbong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeong-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoo-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Sook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June-Won","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoon-Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hawk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Rok","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Gon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hun Ho","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonyang","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Supplement 1","key":"10.1016\/j.leukres.2022.106791_bib0005","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-120367","article-title":"Integrated genome wide association study (GWAS) identifies SNPs associated with outcome in pediatric AML","volume":"132","author":"Elsayed","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2022.106791_bib0010","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1200\/JCO.2009.27.6899","article-title":"Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor","volume":"28","author":"Wagner","year":"2010","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106791_bib0015","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3892\/ol.2020.11650","article-title":"Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis","volume":"20","author":"Liu","year":"2020","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.leukres.2022.106791_bib0020","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2022.106791_bib0025","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2022.106791_bib0030","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.279317","article-title":"Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers","author":"Krishnan","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.leukres.2022.106791_bib0035","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2022.106791_bib0040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.leukres.2009.09.026","article-title":"A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia","volume":"34","author":"de Lavallade","year":"2010","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.leukres.2022.106791_bib0045","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/bloodadvances.2019000195","article-title":"Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib","volume":"3","author":"Kok","year":"2019","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.leukres.2022.106791_bib0050","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1078-0432.CCR-13-2755","article-title":"Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics","volume":"20","author":"Low","year":"2014","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2022.106791_bib0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s43586-021-00056-9","article-title":"Genome-wide association studies","volume":"1","author":"Uffelmann","year":"2021","journal-title":"Nature Rev. Methods Primers"},{"issue":"6","key":"10.1016\/j.leukres.2022.106791_bib0060","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.3259","article-title":"Understanding multicellular function and disease with human tissue-specific networks","volume":"47","author":"Greene","year":"2015","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.leukres.2022.106791_bib0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/CIRCRESAHA.119.315179","article-title":"Integrative omics approach to identifying genes associated with atrial fibrillation","volume":"126","author":"Wang","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.leukres.2022.106791_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13040-016-0082-8","article-title":"Network-based analysis of genetic variants associated with hippocampal volume in Alzheimer\u2019s disease: a study of ADNI cohorts","volume":"9","author":"Song","year":"2016","journal-title":"BioData Min."},{"issue":"10","key":"10.1016\/j.leukres.2022.106791_bib0075","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.leukres.2022.106791_bib0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015222","article-title":"Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.leukres.2022.106791_bib0085","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/cam4.1450","article-title":"A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea","volume":"7","author":"Shin","year":"2018","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.leukres.2022.106791_bib0090","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/nprot.2010.116","article-title":"Data quality control in genetic case-control association studies","volume":"5","author":"Anderson","year":"2010","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.leukres.2022.106791_bib0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nprot.2010.182","article-title":"Basic statistical analysis in genetic case-control studies","volume":"6","author":"Clarke","year":"2011","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.leukres.2022.106791_bib0100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/1756-0500-7-901","article-title":"Genotype harmonizer: automatic strand alignment and format conversion for genotype data integration","volume":"7","author":"Deelen","year":"2014","journal-title":"BMC Res. Notes"},{"issue":"5","key":"10.1016\/j.leukres.2022.106791_bib0105","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/429864","article-title":"A note on exact tests of Hardy-Weinberg equilibrium","volume":"76","author":"Wigginton","year":"2005","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.leukres.2022.106791_bib0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1515\/sagmb-2012-0039","article-title":"The mid p-value in exact tests for Hardy-Weinberg equilibrium","volume":"12","author":"Graffelman","year":"2013","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"issue":"10","key":"10.1016\/j.leukres.2022.106791_bib0115","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.3656","article-title":"Next-generation genotype imputation service and methods","volume":"48","author":"Das","year":"2016","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.leukres.2022.106791_bib0120","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3679","article-title":"Reference-based phasing using the haplotype reference consortium panel","volume":"48","author":"Loh","year":"2016","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.leukres.2022.106791_bib0125","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ng.3571","article-title":"Fast and accurate long-range phasing in a UK Biobank cohort","volume":"48","author":"Loh","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2022.106791_bib0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: rising to the challenge of larger and richer datasets","volume":"4","author":"Chang","year":"2015","journal-title":"GigaScience"},{"issue":"3","key":"10.1016\/j.leukres.2022.106791_bib0135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am. J. Hum. Genet."},{"issue":"Web Server issue","key":"10.1016\/j.leukres.2022.106791_bib0140","doi-asserted-by":"crossref","first-page":"W749","DOI":"10.1093\/nar\/gkq428","article-title":"GSA-SNP: a general approach for gene set analysis of polymorphisms","volume":"38","author":"Nam","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.leukres.2022.106791_bib0145","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1093\/nar\/gky175","article-title":"Efficient pathway enrichment and network analysis of GWAS summary data using GSA-SNP2","volume":"46","author":"Yoon","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"Database issue","key":"10.1016\/j.leukres.2022.106791_bib0150","first-page":"D1049","article-title":"Gene ontology consortium: going forward","volume":"43","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.leukres.2022.106791_bib0155","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s12859-019-3201-y","article-title":"Manhattan++: displaying genome-wide association summary statistics with multiple annotation layers","volume":"20","author":"Grace","year":"2019","journal-title":"BMC Bioinformatics"},{"issue":"11","key":"10.1016\/j.leukres.2022.106791_bib0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013984","article-title":"Enrichment map: a network-based method for gene-set enrichment visualization and interpretation","volume":"5","author":"Merico","year":"2010","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.leukres.2022.106791_bib0165","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.leukres.2022.106791_bib0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2022.106791_bib0175","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/leu.2008.210","article-title":"Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis","volume":"22","author":"Khorashad","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2022.106791_bib0180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2010.65","article-title":"High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2022.106791_bib0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/gcc.22005","article-title":"Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category","volume":"52","author":"Huh","year":"2013","journal-title":"Genes, Chromosomes & Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2022.106791_bib0190","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2009-03-210377","article-title":"SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations","volume":"115","author":"Nowak","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.leukres.2022.106791_bib0195","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.1182\/blood-2011-01-329797","article-title":"A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia","volume":"117","author":"Kim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106791_bib0200","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.leukres.2022.106791_bib0205","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2022.106791_bib0210","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2022.106791_bib0215","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2022.106791_bib0220","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","article-title":"Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients","volume":"41","author":"La Nasa","year":"2013","journal-title":"Exp. Hematol."},{"issue":"25","key":"10.1016\/j.leukres.2022.106791_bib0225","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","article-title":"KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib\/nilotinib strategy","volume":"126","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2022.106791_bib0230","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","article-title":"Development and dynamics of robust T-cell responses to CML under imatinib treatment","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2022.106791_bib0235","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.812.812","article-title":"Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK-Cells","volume":"124","author":"Ilander","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2022.106791_bib0240","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:01:50Z","timestamp":1758934910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":48,"alternative-id":["S0145212622000170"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106791","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106791"}}